University of Innsbruck-ko ikertzaileekin lankidetzan egindako argitalpenak (30)

2024

  1. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

    European Journal of Cancer, Vol. 202

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  3. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13

  2. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

  3. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 188, pp. 131-139

  4. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

    Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4419-4429

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

  3. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 174, pp. 221-231

2021

  1. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial

    Journal of the National Cancer Institute, Vol. 113, Núm. 7, pp. 917-923

  2. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190

  3. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    Radiotherapy and Oncology, Vol. 154, pp. 327-353

  4. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39

2020

  1. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners -a new Model D for drug and medical device development

    International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 730-734

  2. Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: Laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey

    International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 819-824

2019

  1. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    Gynecologic Oncology

  2. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1094-1097

  3. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

  4. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1141-1147